Dr. Peter Canoll is a Professor of Pathology & Cell Biology and Neurosurgical Sciences at Columbia University Irving Medical Center, where he also serves as the Director of Neuropathology. He earned his M.D. and Ph.D. from the New York University School of Medicine, followed by training in Anatomic Pathology at New York Presbyterian Hospital/Cornell Medical Center and a fellowship in Neuropathology at New York Presbyterian Hospital/Columbia University. Dr. Canoll is board-certified in both Anatomic Pathology and Neuropathology by the American Board of Pathology. Dr. Canoll's research focuses on understanding glioma development's molecular and cellular mechanisms and the interactions between glioma cells and the brain microenvironment. His laboratory uses genetically engineered mouse models that mimic the histological and molecular characteristics of human gliomas to investigate the cellular changes that drive gliomagenesis. As the Director of Neuropathology, Dr. Canoll plays a key role in Columbia's Brain Tumor Program, serving as the primary neuropathologist in all clinical trials. Over the past 14 years, he has analyzed and diagnosed hundreds of brain tumors, with the goal of translating his research and clinical expertise into more effective diagnostic tools and treatments for brain tumors.